Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
The use of radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma offers the hope of delivering radiation to tumor with relative specificity, thereby providing significant antitumor effects with limited toxicity. In this article the results of recently initiated trials are summarized, and the major unresolved issues concerning this approach are reviewed.
University of Washington School of Medicine, Seattle.
F R
FR
Appelbaum
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy* / Q000628:therapy; D011868:Radioisotopes / Q000627:therapeutic use*; D014916:Whole-Body Irradiation
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D011868:Radioisotopes